Damora Therapeutics
DMRA
104 hedge funds and large institutions have $1.67B invested in Damora Therapeutics in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 27 increasing their positions, 9 reducing their positions, and 12 closing their positions.
333% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 12
267% more capital inflows, than outflows
Capital inflows: $358M | Capital outflows: $97.6M
200% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 9
60% more funds holding
Funds holding: 65 → 104 (+39)
11.91% more ownership
Funds ownership: 92.86% → 104.77% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$71.2M |
| 2 |
JP Morgan Chase
New York
|
+$49.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$33M |
| 4 |
Braidwell
Stamford,
Connecticut
|
+$17.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.7M |
| 2 |
Bellevue Group
Kuesnacht,
Switzerland
|
-$16.4M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.7M |
| 4 |
Millennium Management
New York
|
-$12.2M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.32M |
DMRA Hedge Fund Activity: Q2 2026 in Review
104 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q2 2026, worth a combined $1.67B — up 15% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new DMRA positions and 12 closed out — a net gain of 40 holders — while 27 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $71.2M. The largest seller was Point72 Asset Management, cutting an estimated $27.7M.
- 104 institutional investors held Damora Therapeutics (DMRA) as of Q2 2026, up from 65 in Q1 2026.
- Funds reported $1.67B of Damora Therapeutics stock for Q2 2026, up 15% quarter-over-quarter.
- 52 funds opened new Damora Therapeutics positions in Q2 2026 and 12 closed out, a net change of +40 holders.
- The largest Damora Therapeutics buyer in Q2 2026 was BlackRock, an estimated $71.2M added.
- The largest Damora Therapeutics seller in Q2 2026 was Point72 Asset Management, an estimated $27.7M sold.
Based on aggregated 13F filings for Q2 2026.